Biotech Values

[read_this_n0w]

2:31PM Myriad Pharma's Azixa is efficacious in a model of human brain cancer and its activity is additive with Avastin (MYRX) 6.77 +0.41 : Co announced the presentation of non-clinical data demonstrating the potent anti-cancer activity of Azixa, its small molecule microtubule destabilizing agent, in a model of brain cancer. Azixa is currently in two phase 2 studies for the treatment of primary brain tumors and one phase 2 trial for the treatment of metastatic melanoma. The data demonstrated that Azixa reduced the growth of glioma tumor cells implanted into the brains of mice by 98%. This reduction in tumor growth significantly improved the survival of Azixa-treated mice when compared with control animals. Data from two additional cancer models demonstrated that the combination of Azixa and Avastin was more efficacious than treatment with Avastin alone.




Azixa = licensed from EPCT (epicept corporation)